Interferon beta-1a
How it works: The first medicines: interferon beta and glatiramer acetate →
Avonex, Rebif
EU: Approved in the EU since 1997US: FDA approved 1996
- Molecule type
- Protein
- Mechanism (ChEMBL)
- Interferon alpha/beta receptor agonist
- Targets
- Interferon alpha/beta receptor
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Other regulatory events
- Application withdrawn · Biferonex28 May 2009 Source
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
192,622 reports in total, 102,510 marked serious.
- Multiple sclerosis relapse15,911
- Influenza like illness13,265
- Fatigue11,574
- Fall10,638
- Multiple sclerosis9,413
- Gait disturbance8,953
- Headache8,437
- Memory impairment8,013
- Pain7,767
- Injection site pain6,338
Trials
Key trials
Large trials with a reported result on their main goal.
- Clinical trial to evaluate the effectiveness and safety of IFN beta-1a
Completed · Phase 3 · Relapsing MS · Missed its main goal
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participant
Completed · Phase 3 · Relapsing MS · Shown as good as the comparator
- Efficacy and Safety Study of Peginterferon Beta-1a in Participants Wit
Completed · Phase 3 · Relapsing MS · Met its main goal
- Oral Cladribine in Early Multiple Sclerosis (MS)
Completed · Phase 3 · Early (CIS/RIS) · Met its main goal
- Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLE
Completed · Phase 3 · Early (CIS/RIS) · Met its main goal
- Immunogenicity and Safety of Subcutaneously-administered Avonex (Inter
Terminated · Phase 3 · Relapsing MS · Stopped: safety
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, S
Completed · Phase 3 · Relapsing MS · Met its main goal
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, S
Completed · Phase 3 · Relapsing MS · Met its main goal
- RNF and Betaseron® Tolerability Study
Completed · Phase 3 · Relapsing MS · Missed its main goal
- A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Rel
Completed · Phase 3 · Relapsing MS · Met its main goal
Running now
- A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Mai
Recruiting · Phase 3 · Relapsing and progressive · Still running
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Not yet recruiting · Phase 3 · Relapsing MS · Still running
- An Observational Study to Learn About the Interferon-beta Exposure of
Running, not recruiting · MS (type not specified) · Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting · Relapsing MS · Still running
- Disease Modifying Therapies Withdrawal in Inactive Secondary Progressi
Running, not recruiting · Phase 3 · Progressive MS · Still running
Other trials (89)
Completed small trials, dose-finding studies and trials in other diseases.
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Terminated · Phase 4 · Relapsing MS · Stopped
- A Post-Authorization Safety Study of Interferon Beta Therapy in Partic
Completed · Relapsing MS · No results found
- Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance
Completed · Phase 2 / Phase 3 · Relapsing MS · No results found
- MEasuring Satisfaction of Treatment With REbif After Initial Treatment
Terminated · Relapsing MS · Stopped
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Tran
Completed · Phase 4 · Relapsing MS · No results found
- Non-interventional Study to Assess Adherence to Treatment for Patients
Completed · Relapsing MS · Paper found, not read
- EPID Multiple Sclerosis Pregnancy Study
Completed · MS (type not specified) · No results found
- Patient Real-world Clinical, Neurological, Tolerability, and Safety Ou
Completed · Relapsing MS · No results found
- Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Pat
Withdrawn · Relapsing MS · Stopped
- Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment
Completed · Phase 2 / Phase 3 · Relapsing MS · Results posted, not judged
Trials where it is given as background therapy
- Drug Repurposing Using Metformin for Improving the Therapeutic Outcome
Status unknown · Phase 2 · MS (type not specified) · Missed its main goal
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or G
Withdrawn · Phase 2 · Relapsing and progressive · Stopped: not working
- A Pilot Study in Participants With Relapsing Remitting Multiple Sclero
Terminated · Phase 2 · Relapsing MS · Stopped
- Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokineti
Completed · Phase 2 · Relapsing and progressive · Met its main goal
- Dietary Supplement of Curcumin in Subjects With Active Relapsing Multi
Completed · Phase 2 · Relapsing MS · Missed its main goal
- National Multicenter, Controlled, Single-blind Study With Two Parallel
Completed · Phase 3 · MS (type not specified) · No results found
- A Multicentre Study of the Efficacy and Safety of Supplementary Treatm
Completed · Phase 2 · Relapsing MS · Missed its main goal
- Long Term Safety of Teriflunomide When Added to Interferon-Beta or Gla
Completed · Phase 2 · MS (type not specified) · Main goal was not benefit
- Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-be
Completed · Phase 2 · MS (type not specified) · Main goal was not benefit
- Combination Therapy Using Cellcept and Rebif in RRMS
Completed · Early phase 1 · Relapsing MS · No results found
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…